SK biopharm’s U.S. R&D subsidiary, Proteovant Therapeutics, announced on Sept. 27 that it will present its latest research findings in the Targeted Protein Degradation (TPD) field at the “Discovery on Target 2023” held in Boston, Massachusetts, from Sept. 27 to 28, local time.
In this presentation, Proteovant will debut its innovative platform for the discovery of Molecular Glue, Molecular Glue Screening Platform, and the excellent drug-like properties and preclinical efficacy results of selective molecular glues targeting IKZF2, an immune anti-cancer target.
MOPED offers a new method for identifying molecular glues that can destroy malfunctioning proteins, kill cancer cells, or inhibit their growth. Molecular glues, smaller in molecular weight than conventional PROTACs, allow for targeted protein degradation, promising accelerated development and potential applications in expanded disease areas, establishing them as the next generation in the TPD domain.
SK biopharm and Proteovant are actively exploring and developing best-in-class and first-in-class degraders that can target previously untreatable markers through TPD research and MOPED.
Recently, SK biopharm highlighted TPD as one of the new therapeutic methodologies in their Financial Story. TPD technology leverages the body’s protein degradation system to remove target proteins causing diseases, recognized as one of the most promising platforms for next-generation drug development. In pursuit of this, SK biopharm acquired Proteovant last July, securing global-level TPD research and development capabilities. Collaborative synergy between SK’s investment capabilities and SK biopharm’s drug development expertise has produced research achievements in the promising field of TPD.